BioSpace News Archive

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 24-week results from the global Phase 3 open-label study evaluating the safety and tolerability of investigational oral edaravone in the treatment of amyotrophic lateral sclerosis (ALS). Findings from the Phase 3 study, which is conducted by Mitsubishi.

Products in the Bowie Dick test pack market, are chemical indicators used at a daily basis in order to assess the performance of various air removal systems including autoclaves.

The global MR vital sign monitors will see a significant increase in demand due to rising requests from clinicians and patients in 2020 owing to the emergence of the Covid-19 issue, As people’s awareness of health issues grows in 2021, healthcare professionals will require new and upgraded vital sign monitors for more complete tracking and monitoring of patients, resulting in increased demand.

iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode of action of its autotaxin inhibitor IOA-289 and showing preclinical evidence of the role of autotaxin inhibition in breaking down tumor resistance mechanisms.

Following months of collaborative development work, Aerogen® and CanSinoBIO have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.

RhoVac AB, a Swedish cancer immunotherapy company, announces on December 9th, 2021, that its Data & Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, expanded its ultrasound portfolio with new robust imaging tools and features for Cardiology to increase diagnostic confidence and workflow efficiency.

SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented interim results from the highest-dose cohort of its ongoing Phase 1/2 clinical trial of lead Antigen Presenting Cell (APC) therapy candidate targeting Human Papillomavirus positive (HPV16+) solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress.

Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., announced that Allegheny Health Network, a Highmark Health Company, has selected Sun Nuclear as its radiation therapy Quality Assurance solutions partner.

Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence.